BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30

• 

  Earnings

  Pfizer Announces Another $1.7B in Cost Savings, Including R&D Revamp

  Pfizer’s R&D organization has been in flux for almost two years now, since the $43 billion acquisition of ADC specialist Seagen. The new cuts were revealed in the company’s Q1 earnings report.

  April 29, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Vaccines

  HHS Unfreezes Vaxart’s COVID-19 Study, Resumes Funding as Headwinds Batter Vaccines Space

  While Vaxart can proceed with its study, fellow COVID-19 vaccine developers GeoVax and Novavax continue to be hamstrung by various regulatory roadblocks.

  April 29, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Pipeline

  AstraZeneca Abandons Neuroscience, Prioritizes Weight Loss, Immunology

  Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro altogether.

  April 29, 2025

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Rare diseases

  Abeona Gets FDA Nod for Rare Skin Disease Gene Therapy

  The condition, recessive dystrophic epidermolysis bullosa, causes chronic wounds and has an 84% mortality rate by age 40.

  April 29, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  Earnings

  Novartis CEO Brushes Off Tariffs but Says Trump Pricing Controls Would Be ‘Devastating’

  Vas Narasimhan said on Tuesday that if the U.S. adopts international drug pricing, all companies would have to “relook at their medium- to long-term outlook.”

  April 29, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Mergers & acquisitions

  Biohaven Grabs a Foothold With $600M Windfall From Oberland Capital

  Biohaven will use the money to bankroll commercial preparations for the spinocerebellar ataxia drug candidate troriluzole, which is currently under FDA review with a decision expected in the third quarter.

  April 29, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Layoffs

  Octagon Winds Down After Deprioritizing Lead Program

  Despite executing perfectly, Octagon confronted a “scientific no-go,” CEO Isaac Stoner said in his LinkedIn post announcing the company’s impending closure.
  

  April 29, 2025

   · 

  1 min read

   · 

  Angela Gabriel
• 

  Earnings

  Pfizer CEO Calls Trump’s Pharma National Security Concerns ‘Legitimate’

  Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the pharmaceutical industry tariffs, which Trump has threatened, in part as a way to shore up U.S. national security.

  April 29, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Manufacturing

  With Pharma Throwing Billions At US Manufacturing, Where Is The Cash Going?

  Major pharmaceutical companies are committing billions to US manufacturing in an effort to avoid steep tariffs threatened by President Donald Trump.

  April 29, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  FDA

  FDA Alumni, Experts Call on Makary To Stand Up Against Agency’s Politicization

  In a recent interview, FDA Commissioner Marty Makary said there “should be nothing political about the FDA.” Recent actions taken by HHS Secretary Robert F. Kennedy, Jr. and others within the department appear to be at odds with this sentiment.

  April 29, 2025

   · 

  6 min read

   · 

  Heather McKenzie